Health TidingsWhat Is SD-101? Paradigm’s Investigational Therapy for Epidermolysis Bull... What Is SD-101? Paradigm’s Investigational Therapy for Epidermolysis Bull... Read Post »
Health Tidings Mergers & AcquisitionsGenerate Signs $1.2B Milestone Deal with Zealand for AI-Designed Protein Dr... Generate Signs $1.2B Milestone Deal with Zealand for AI-Designed Protein Dr... Read Post »
Health TidingsOnswik Secures UK Authorisation as Once-Weekly Insulin Offers an Alternativ... Onswik Secures UK Authorisation as Once-Weekly Insulin Offers an Alternativ... Read Post »
Clinical TrialsSKYRIZI Achieves 35.8% Remission in AFFIRM Crohn’s Trial SKYRIZI Achieves 35.8% Remission in AFFIRM Crohn’s Trial Read Post »
Clinical TrialsBiomea’s Oral GLP-1 Candidate BMF-650 Shows Early Weight Loss Biomea’s Oral GLP-1 Candidate BMF-650 Shows Early Weight Loss Read Post »
Clinical TrialsBeam Reports Improved Fasting Tolerance With BEAM-301 Base Editing in GSDIa Beam Reports Improved Fasting Tolerance With BEAM-301 Base Editing in GSDIa Read Post »
Health TidingsEntera Bio Reports Up to 4.23% Hip BMD Gain with Oral EB613 in Osteoporosis... Entera Bio Reports Up to 4.23% Hip BMD Gain with Oral EB613 in Osteoporosis... Read Post »
Health TidingsNImmune Reports Omilancor Cuts Biologic-Refractoriness Gene Signature by Ov... NImmune Reports Omilancor Cuts Biologic-Refractoriness Gene Signature by Ov... Read Post »
Health Tidings Mergers & AcquisitionsPrelude and Lilly Partner to Test PRT13722 Combinations in HR+/HER2− Brea... Prelude and Lilly Partner to Test PRT13722 Combinations in HR+/HER2− Brea... Read Post »
Health TidingsZydus, Formycon Advance First Publicly Announced Keytruda Biosimilar into F... Zydus, Formycon Advance First Publicly Announced Keytruda Biosimilar into F... Read Post »
Clinical Trialsāshibio Reports 86.2% Lower FOP Flare-Up, Advances Vantictumab for ADO2 āshibio Reports 86.2% Lower FOP Flare-Up, Advances Vantictumab for ADO2 Read Post »
Clinical TrialsTREMFYA Shows Fistula Remission in Crohn’s Disease TREMFYA Shows Fistula Remission in Crohn’s Disease Read Post »
Clinical TrialsSyndax Ends Axatilimab Development in IPF After Phase 2 Failure Syndax Ends Axatilimab Development in IPF After Phase 2 Failure Read Post »
Health TidingsEleven Therapeutics Spinout Undecimal Bio Raises $18M to Advance siRNA Deli... Eleven Therapeutics Spinout Undecimal Bio Raises $18M to Advance siRNA Deli... Read Post »
Clinical TrialsBioNTech BNT113 Misses PFS Endpoint in HPV16+ HNSCC Trial BioNTech BNT113 Misses PFS Endpoint in HPV16+ HNSCC Trial Read Post »
Health Tidings Mergers & AcquisitionsRoche and Rona Sign $1.16B Deal for ALK7-Targeting RNAi Obesity Candidate Roche and Rona Sign $1.16B Deal for ALK7-Targeting RNAi Obesity Candidate Read Post »
Health TidingsRegeneron Reports Zero New Bone Lesions With Pasatru in OPTIMA Extension Regeneron Reports Zero New Bone Lesions With Pasatru in OPTIMA Extension Read Post »
Health TidingsTREMFYA Delivers 3-Year Clinical and Endoscopic Remission in Crohn’s Dise... TREMFYA Delivers 3-Year Clinical and Endoscopic Remission in Crohn’s Dise... Read Post »
Health TidingsZydus’ Saroglitazar Shows Higher PBC Biochemical Response Across Geog... Zydus’ Saroglitazar Shows Higher PBC Biochemical Response Across Geog... Read Post »
Health TidingsImmuron’s Travelan Shows 40% Reduction in ETEC-Associated Travellers’ D... Immuron’s Travelan Shows 40% Reduction in ETEC-Associated Travellers’ D... Read Post »
Clinical TrialsTortugas Reports Positive Phase 2b Results for Obuprazine in Schizophrenia Tortugas Reports Positive Phase 2b Results for Obuprazine in Schizophrenia Read Post »
Clinical TrialsMirum’s LIVMARLI Cuts Bile Acids by 70%, Improves Itching in Phase 3 Tria... Mirum’s LIVMARLI Cuts Bile Acids by 70%, Improves Itching in Phase 3 Tria... Read Post »
Clinical TrialsAstraZeneca’s Efzimfotase Alfa Misses Endpoint in Hypophosphatasia Tr... AstraZeneca’s Efzimfotase Alfa Misses Endpoint in Hypophosphatasia Tr... Read Post »
Health TidingsTG Reports Lower Disability Progression With BRIUMVI in Five-Year Analysis TG Reports Lower Disability Progression With BRIUMVI in Five-Year Analysis Read Post »
Health TidingsCervoMed Reports 12-Week NfL Reduction with Neflamapimod in Phase 2a nfvPPA... CervoMed Reports 12-Week NfL Reduction with Neflamapimod in Phase 2a nfvPPA... Read Post »
Clinical TrialsANI Reports Long-Term Uveitis Results Alongside IOP-Related Safety Findings ANI Reports Long-Term Uveitis Results Alongside IOP-Related Safety Findings Read Post »
Clinical TrialsBMS Reports Admilparant 60 mg Meets Endpoint in IPF Trial, 120 mg Falls Sho... BMS Reports Admilparant 60 mg Meets Endpoint in IPF Trial, 120 mg Falls Sho... Read Post »
Clinical TrialsAbbVie Presents SKYRIZI Remission Results and RINVOQ Real-World Outcomes AbbVie Presents SKYRIZI Remission Results and RINVOQ Real-World Outcomes Read Post »
Health TidingsLeads Biolabs’ Opamtistomig Gets FDA Fast Track for BTC Leads Biolabs’ Opamtistomig Gets FDA Fast Track for BTC Read Post »
Health TidingsIdorsia’s Aprocitentan Lowers Blood Pressure Across CKM Stages Idorsia’s Aprocitentan Lowers Blood Pressure Across CKM Stages Read Post »
Clinical TrialsAcoramidis Shows 34% Lower Hazard of Composite Clinical Worsening Than Tafa... Acoramidis Shows 34% Lower Hazard of Composite Clinical Worsening Than Tafa... Read Post »
Clinical TrialsClinical Remission Reaches 71.4% With Subcutaneous Infliximab in Matched Cr... Clinical Remission Reaches 71.4% With Subcutaneous Infliximab in Matched Cr... Read Post »
Health TidingsClaris Reports Sustained Visual Gains With CSB-001 in LSCD Study Claris Reports Sustained Visual Gains With CSB-001 in LSCD Study Read Post »
Health TidingsSebela’s Tegoprazan Improves Heartburn and Regurgitation in Phase 3 NERD ... Sebela’s Tegoprazan Improves Heartburn and Regurgitation in Phase 3 NERD ... Read Post »
Health TidingsRemigromig Shows Non-Inferior Visual Acuity in DME, With a PDR-Related Safe... Remigromig Shows Non-Inferior Visual Acuity in DME, With a PDR-Related Safe... Read Post »
Clinical TrialsRoche Reports Sustained Vision and Anatomical Improvements with Vamikibart ... Roche Reports Sustained Vision and Anatomical Improvements with Vamikibart ... Read Post »
Clinical TrialsBridgeBio’s Encaleret Shows PTH Recovery and Symptom Improvements in ... BridgeBio’s Encaleret Shows PTH Recovery and Symptom Improvements in ... Read Post »
Clinical TrialsCardurion’s Tovinontrine Phase 2 Results Show Greater NT-proBNP Reduc... Cardurion’s Tovinontrine Phase 2 Results Show Greater NT-proBNP Reduc... Read Post »
Health TidingsChai Discovery’s AI Models Identify Binders Across All GSK Targets Tested Chai Discovery’s AI Models Identify Binders Across All GSK Targets Tested Read Post »
Clinical TrialsVertex Reports Promising Pancreatic Function Gains With ALYFTREK in Young C... Vertex Reports Promising Pancreatic Function Gains With ALYFTREK in Young C... Read Post »
Clinical TrialsSling’s Linsitinib Maintains Proptosis Response Through Week 72 in LI... Sling’s Linsitinib Maintains Proptosis Response Through Week 72 in LI... Read Post »
New Drug ApprovalFDA Approves HOVILPRI for Refractory HSV Lesions in Immunocompromised Adult... FDA Approves HOVILPRI for Refractory HSV Lesions in Immunocompromised Adult... Read Post »
Health TidingsDenifanstat Cuts Acne Lesions by 72% at 52 Weeks, With 57% Treatment Succes... Denifanstat Cuts Acne Lesions by 72% at 52 Weeks, With 57% Treatment Succes... Read Post »
Health TidingsMineralys Reports 46% Reaching SBP Target at Week 12 and 11.1 mmHg Reductio... Mineralys Reports 46% Reaching SBP Target at Week 12 and 11.1 mmHg Reductio... Read Post »
Health TidingsVir’s VIR-5500 Fast Track by FDA for Advanced Prostate Cancer Vir’s VIR-5500 Fast Track by FDA for Advanced Prostate Cancer Read Post »
Clinical TrialsICOTYDE Sustains PASI 90 Response Through Two Years ICOTYDE Sustains PASI 90 Response Through Two Years Read Post »
Clinical TrialsLilly’s Taltz–Zepbound Study Links Neutrophils to Psoriasis Response Lilly’s Taltz–Zepbound Study Links Neutrophils to Psoriasis Response Read Post »
Health TidingsGlaukos Reports 3.6 mmHg Added IOP Reduction With iDose TR During Cataract ... Glaukos Reports 3.6 mmHg Added IOP Reduction With iDose TR During Cataract ... Read Post »
Clinical TrialscAMPfield’s Prifemilast Shows 29.3-Point PASI 75 Advantage Over Aprem... cAMPfield’s Prifemilast Shows 29.3-Point PASI 75 Advantage Over Aprem... Read Post »
New Drug ApprovalFDA Approves Tecentriq Plus Chemotherapy for Stage III dMMR Colon Cancer FDA Approves Tecentriq Plus Chemotherapy for Stage III dMMR Colon Cancer Read Post »
